Core Viewpoint - Fengyuan Pharmaceutical (000153) has experienced a decline in stock price, closing at 6.41 yuan, down 2.14% from the previous week, with a current market capitalization of 2.914 billion yuan [1] Company Announcements - The company will hold its 10th Board of Directors' fourth (temporary) meeting on December 29, 2025, to review the proposal for increasing capital to Hefei Hongfeng Equity Investment Fund Center (Limited Partnership) [2] - Fengyuan Pharmaceutical plans to increase its investment by 53 million yuan, raising its total contribution to 203 million yuan, which will account for 47.21% of the fund's total subscribed capital [2] - Following this capital increase, the fund's size will grow from 310 million yuan to 430 million yuan [2]

截至2025年12月30日收盘，丰原药业(000153)报收于6.31元，下跌0.32%，换手率1.05%，成交量4.85万 手，成交额3064.67万元。 关于向合肥弘丰股权投资基金中心（有限合伙）增资的公告 当日关注点 安徽丰原药业股份有限公司拟以自有资金向合肥弘丰股权投资基金中心（有限合伙）增资5,300万元人 民币，出资总额由15,000万元增至20,300万元，占基金总认缴出资额的47.21%。本次增资后，基金规模 由3.1亿元增至4.3亿元。该事项已获公司董事会审议通过，不构成关联交易或重大资产重组。公司强调 资金来源为自有资金，不影响正常经营，但提示投资存在周期长、收益不确定等风险。 交易信息汇总资金流向 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 12月30日主力资金净流入204.8万元；游资资金净流出53.4万元；散户资金净流出151.41万元。 来自交易信息汇总：12月30日主力资金净流入204.8万元，显示主力对个股短期态度偏积极。 来自公司公告汇总：丰原药业拟以自有资金向合肥弘丰股权投资基金中心（有限合伙 ...

Core Viewpoint - The company has approved a capital increase of 53 million RMB to the Hefei Hongfeng Equity Investment Fund Center (Limited Partnership) to support the fund's business development [2][6]. Group 1: Board Meeting and Decision - The company's 10th fourth (temporary) board meeting was held on December 29, 2025, with all six attending directors present, and the meeting was chaired by Chairman Li Yang [1]. - The board unanimously approved the proposal to increase capital to the Hefei Hongfeng Equity Investment Fund Center [2][3]. Group 2: Investment Fund Overview - The company initially invested 150 million RMB to establish the Hefei Hongfeng Equity Investment Fund Center [5]. - The fund completed its private investment fund registration on February 5, 2024, with the China Securities Investment Fund Industry Association [5]. Group 3: Capital Increase Details - The total capital increase for the fund amounts to 120 million RMB, with the company's contribution being 53 million RMB [6]. - The fund's scale will increase from 310 million RMB to 430 million RMB following this capital increase [6]. Group 4: Impact and Compliance - The capital increase will not affect the company's normal operations or financial status significantly [6]. - The investment does not constitute a related party transaction or a major asset restructuring as per regulations [6].

Key Points - Guizhou Moutai's controlling shareholder, Moutai Group, has completed a share buyback plan, acquiring 2,071,359 shares for a total of 3 billion yuan, increasing its stake to 56.63% of the total share capital [1] - Juneyao Airlines plans to purchase 25 Airbus A320 series aircraft for a total of 4.1 billion USD, with deliveries scheduled between 2028 and 2032 [1] - ST Panda is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [1] - Huali Co. has terminated its plan to acquire a 51% stake in Zhongke Huilian due to a lack of consensus on key transaction terms [1][2] - China Duty Free Group's subsidiary has signed a contract for a duty-free project at Beijing Capital International Airport, covering an area of 10,646.74 m², with a guaranteed operating fee of 480.27 million yuan in the first year [3] - Haisheng Pharmaceutical's invested company has initiated Phase II clinical trials for NWRD06, a novel RNA drug targeting GPC3 for liver cancer, marking a significant milestone in cancer treatment [3] - WISCO Development is planning to acquire stakes in WISCO Mining and Luzhong Mining through asset swaps and cash payments, leading to a temporary suspension of its stock [4] - Yonghui Supermarket intends to publicly sell a 28.095% stake in its subsidiary Yonghui Cloud Gold Technology [5] - Shanxi Expressway plans to acquire a 15% stake in Shanxi Transportation Industry Development Group for 74.8 million yuan [5] - China Energy Construction's subsidiary has won a 6.864 billion yuan ecological comprehensive governance project [5]

格隆汇12月29日丨丰原药业(000153.SZ)公布，公司本次拟以自有资金向弘丰基金增资5,300万元人民 币。该事项已经公司2025年12月29日召开的第十届四次（临时）董事会会议审议通过。弘丰基金各合伙 人本次增资合计12,000万元。基于上述合伙份额变动事项，公司与弘丰基金普通合伙人北京京工弘元投 资管理有限公司以及有限合伙人上海朴弘投资有限公司、北京九城投资有限公司、北京雄越投资管理有 限公司重新签署《合肥弘丰股权投资基金中心（有限合伙）合伙协议》。 ...

（编辑 丛可心） 证券日报网讯 12月29日，丰原药业发布公告称，丰原药业第十届四次（临时）董事会于2025年12月29 日审议通过《关于向合肥弘丰股权投资基金中心（有限合伙）增资的议案》，同意以自有资金向该基金 增资5300万元，6票全票通过。 ...

每经AI快讯，丰原药业（SZ 000153，收盘价：6.33元）12月29日晚间发布公告称，公司第十届四次董 事会会议于2025年12月29日在公司办公楼第一会议室召开。会议审议了《关于向合肥弘丰股权投资基金 中心（有限合伙）增资的议案》等文件。 每经头条（nbdtoutiao）——绕开光刻机"卡脖子"，中国新型芯片问世！专访北大孙仲：支撑AI训练和 具身智能，可在28纳米及以上成熟工艺量产 （记者 王晓波） 2025年1至6月份，丰原药业的营业收入构成为：药品零售流通占比63.78%，药品生产制造占比34.4%， 其他业务占比1.82%。 截至发稿，丰原药业市值为29亿元。 ...

股票简称：丰原药业 股票代码：000153 公告编号：2025-045 安徽丰原药业股份有限公司关于 向合肥弘丰股权投资基金中心（有限合伙） 增资的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或 者重大遗漏。 一、合作设立投资基金的概述 3、2024 年 10 月 9 日，公司在巨潮资讯网披露的《关于与专业投资机构共同投 资产业基金进展的公告》（公告编号：2024-029）。 4、公司本次拟以自有资金向弘丰基金增资 5,300 万元人民币。该事项已经公司 2025 年 12 月 29 日召开的第十届四次（临时）董事会会议审议通过。弘丰基金各合 伙人本次增资合计 12,000 万元。基于上述合伙份额变动事项，公司与弘丰基金普通 合伙人北京京工弘元投资管理有限公司以及有限合伙人上海朴弘投资有限公司、北 京九城投资有限公司、北京雄越投资管理有限公司重新签署《合肥弘丰股权投资基 金中心（有限合伙）合伙协议》。 5、本次对外投资事项在公司董事会审议权限范围内，无需提交公司股东会审议。 本次对外投资事项不构成关联交易，亦不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 ...

安徽丰原药业股份有限公司 第十届四次(临时)董事会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或 者重大遗漏。 安徽丰原药业股份有限公司（下称"公司"）第十届四次（临时）董事会于 2025 年 12 月 29 日在公司办公楼第一会议室召开。本次会议通知于 2025 年 12 月 24 日以 送达或电子邮件等方式向公司全体董事、部分高级管理人员发出。参加本次会议的 董事应到 6 人，实到 6 人。公司部分高级管理人员列席了会议。会议由公司董事长 李阳先生主持。会议召开符合《中华人民共和国公司法》及《公司章程》的有关规 定。 经与会董事认真审议，并以记名式书面表决的方式，一致通过如下议案： 通过《关于向合肥弘丰股权投资基金中心（有限合伙）增资的议案》 股票简称：丰原药业 股票代码：000153 公告编号：2025-044 具体事项请详见公司于巨潮资讯网（http://www.cninfo.com.cn）刊登的《关于向 合肥弘丰股权投资基金中心（有限合伙）增资的公告》（公告编号：2025-045）。 安徽丰原药业股份有限公司 董 事 会 二〇二五年十二月二十九日 因基金业 ...

Group 1 - Rhine Biotech's controlling shareholder is planning a change in control and intends to acquire at least 80% of Beijing Jinkangpu's equity [1] - The transaction is still in negotiation stages, and the final agreement will depend on further discussions [1] - The acquisition aims to introduce new resources and expand business boundaries [1] Group 2 - Huatai Medical plans to repurchase shares with a total fund of no less than 200 million yuan and not exceeding 250 million yuan [2] - The repurchase price will not exceed 315 yuan per share, and the period is set for 10 months from the board's approval [2] - The repurchased shares will be used for employee stock ownership plans or equity incentives [2] Group 3 - Fengyuan Pharmaceutical's shareholder, Bengbu Tushan Enterprise Management Co., has pledged 32.36 million shares [3] - The pledge ratio for some shareholders is close to 100%, indicating potential risks related to share pledges [3] - Despite the high pledge ratios, the company's normal operations remain unaffected [3] Group 4 - Saint Gene Biotech has completed a Series B financing round of over 110 million USD [4] - The funds will be used to advance the development of RNAi therapies, particularly leveraging their new delivery platform [4] - This financing aligns with industry trends and is expected to enhance the company's competitive edge in the RNAi innovation field [4]